Jefferies expects positive FDA panel for NPS Pharmaceuticals

Jefferies expects the October 16 FDA Gastrointestinal Drugs Advisory Committee panel for NPS Pharmaceuticals' Gattex will be positive. The firm assumes a 90% probability for a positive regulatory outcome for Gattex and keeps a Buy rating on the stock with a $13 price target.